PharmaShots | Incisive News in 3 Shots

Subscribe Now

EMA

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

November 21, 2024

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

October 30, 2024

New Drug Designations - September 2024

New Drug Designations - September 2024

October 29, 2024

Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

October 28, 2024

Alnylam Reports the Submission of Regulatory Application of Amvuttra (Vutrisiran) to the EMA Treating ATTR Amyloidosis with Cardiomyopathy

Alnylam Reports the Submission of Regulatory Application of Amvuttra (Vutrisiran) to the EMA Treating ATTR Amyloidosis with Cardio...

October 17, 2024

Merck Animal Health Reports the EMA’s Approval of an Expanded Indication for SC Administration of Bovilis Rotavec Corona

Merck Animal Health Reports the EMA’s Approval of an Expanded Indication for SC Administration of Bovilis Rotavec Corona

October 16, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us